Background: Slow flow/no-reflow (SF-NR) complicates up to 44% of percutaneous #coronary interventions ( #PCI) for acute myocardial infarction (#AMI), worsening prognosis. Electroacupuncture (EA) may mitigate SF-NR, but clinical evidence is limited.Objective: This trial was designed to assess the feasibility and effectiveness of intraoperative EA in reducing SF-NR during PCI for AMI patients.Design setting and participants… Continue reading Electroacupuncture for slow flow/no-reflow in patients with acute myocardial infarction undergoing percutaneous coronary intervention: a pilot randomized controlled trial
Tag: PCI
Prognostic and Practical Validation of ESC/EACTS High #Ischemic Risk Definition on Long-Term Thrombotic and Bleeding Events in Contemporary #PCI Patients
The ESC/EACTS myocardial revascularization guidelines recently standardized the definition of patients at high ischemic risk (HIR). However, the ability of ESC/EACTS-HIR criteria to stratify ischemic and bleeding risk in a contemporary real-world East Asian cohort remains unexplored. Methods: A total of 10,167 consecutive patients undergoing PCI from prospective Fuwai PCI Registry (January 2013 to December… Continue reading Prognostic and Practical Validation of ESC/EACTS High #Ischemic Risk Definition on Long-Term Thrombotic and Bleeding Events in Contemporary #PCI Patients
Prognostic Impact of Race in Patients Undergoing PCI: Analysis From 10 Randomized Coronary Stent Trials
..Among 22,638 patients, 20,585 (90.9%) were white, 918 (4.1%) were black, 404 (1.8%) were Asian, and 473 (2.1%) were Hispanic. Baseline and angiographic characteristics differed among groups. Five-year major adverse cardiac event rates were 18.8% in white patients (reference group), compared with 23.9% in black patients (p = 0.0009), 11.2% in Asian patients (p =… Continue reading Prognostic Impact of Race in Patients Undergoing PCI: Analysis From 10 Randomized Coronary Stent Trials
Ticagrelor with or without Aspirin in High-Risk Patients after PCI
Monotherapy with a P2Y12 inhibitor after a minimum period of dual antiplatelet therapy is an emerging approach to reduce the risk of bleeding after percutaneous coronary intervention (PCI). ..The difference in risk between the groups was similar for BARC type 3 or 5 bleeding (incidence, 1.0% among patients receiving ticagrelor plus placebo and 2.0% among… Continue reading Ticagrelor with or without Aspirin in High-Risk Patients after PCI
Five-Year Outcomes after PCI or CABG for Left Main Coronary Disease
..In the PCI and CABG groups, the incidences of definite cardiovascular death (5.0% and 4.5%, respectively; difference, 0.5 percentage points; 95% CI, −1.4 to 2.5) and myocardial infarction (10.6% and 9.1%; difference, 1.4 percentage points; 95% CI, −1.3 to 4.2) were not significantly different. All cerebrovascular events were less frequent after PCI than after CABG… Continue reading Five-Year Outcomes after PCI or CABG for Left Main Coronary Disease
2 Medical News 